Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Lung Cancer
Interventions
DRUG

bortezomib

DRUG

docetaxel

Trial Locations (21)

19107

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia

27710

Duke Comprehensive Cancer Center, Durham

30033

Veterans Affairs Medical Center - Atlanta (Decatur), Decatur

30322

Winship Cancer Institute of Emory University, Atlanta

33136

University of Miami Sylvester Cancer Center, Miami

55422

Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale

63110

Siteman Cancer Center, St Louis

St. Louis University Hospital Cancer Center, St Louis

64111

Kansas City Cancer Centers - Central, Kansas City

77030

University of Texas - MD Anderson Cancer Center, Houston

80010

University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora

84112

Huntsman Cancer Institute, Salt Lake City

90048

Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles

90095

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

35233-2115

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

06520-8028

Yale Comprehensive Cancer Center, New Haven

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

28232-2861

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte

37232-6868

Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville

53792-5666

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00064012 - Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter